Literature DB >> 2808215

The pharmacokinetics of meropenem in volunteers.

R P Bax1, W Bastain, A Featherstone, D M Wilkinson, M Hutchison, S J Haworth.   

Abstract

Two human volunteer studies were performed with meropenem: a dose proportionality study of 0.25, 0.5 and 1.0 g and a probenecid interaction study. Six volunteers took part in each study. Meropenem was generally well tolerated: One volunteer was withdrawn from the dose proportionality study because of looseness of stool and abdominal pain after a dose of 1.0 g. The plasma concentrations of meropenem were linearly related to dose. The half-life of meropenem was approximately 1 h and the urinary recovery of unchanged drug was 79%. In the presence of probenecid the plasma half-life of meropenem was increased by 33% but the urinary recovery was unaffected.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2808215     DOI: 10.1093/jac/24.suppl_a.311

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  43 in total

1.  Effect of probenecid on the kinetics of a single oral 400mg dose of moxifloxacin in healthy male volunteers.

Authors:  H Stass; R Sachse
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Pharmacokinetics of meropenem in subjects with various degrees of renal impairment.

Authors:  B A Christensson; I Nilsson-Ehle; M Hutchison; S J Haworth; B Oqvist; S R Norrby
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

3.  Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo.

Authors:  Kathleen England; Helena I M Boshoff; Kriti Arora; Danielle Weiner; Emmanuel Dayao; Daniel Schimel; Laura E Via; Clifton E Barry
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

4.  Pharmacokinetics of the penem CP-65,207 and its separate stereoisomers in humans.

Authors:  G Foulds; A K Knirsch; J D Lazar; T G Tensfelt; N Gerber
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

5.  Pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem, in healthy male Caucasian volunteers.

Authors:  Takahiro Shibayama; Yoko Matsushita; Takashi Hirota; Toshihiko Ikeda; Shogo Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

6.  Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.

Authors:  Phillip J Bergen; Jürgen B Bulitta; Carl M J Kirkpatrick; Kate E Rogers; Megan J McGregor; Steven C Wallis; David L Paterson; Roger L Nation; Jeffrey Lipman; Jason A Roberts; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 7.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

8.  Effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in rats and rabbits.

Authors:  S H Kim; W B Kim; M G Lee
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 9.  Meropenem clinical pharmacokinetics.

Authors:  J W Mouton; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

10.  Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa.

Authors:  R White; L Friedrich; D Burgess; D Warkentin; J Bosso
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.